ANIP Ani Pharmaceuticals Inc
Price (delayed)
$57.94
Market cap
$1.22B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$1.7B
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers),
Highlights
Ani Pharmaceuticals's revenue has increased by 24% YoY and by 3.1% from the previous quarter
The gross profit has grown by 17% year-on-year
Ani Pharmaceuticals's net income has shrunk by 153% YoY and by 126% QoQ
The company's EPS has shrunk by 147% QoQ
Key stats
What are the main financial stats of ANIP
Market
Valuations
Earnings
Shares outstanding
21.03M
Market cap
$1.22B
Enterprise value
$1.7B
Price to earnings (P/E)
N/A
Price to book (P/B)
3
Price to sales (P/S)
2.02
EV/EBIT
172.81
EV/EBITDA
23.7
EV/Sales
3.06
Revenue
$555.46M
Gross profit
$332.11M
Operating income
$14.91M
Net income
-$7.09M
EBIT
$9.83M
EBITDA
$71.67M
Free cash flow
$90.29M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.57
Free cash flow per share
$4.65
Book value per share
$19.29
Revenue per share
$28.63
TBVPS
$33.87
Total assets
$1.29B
Total liabilities
$856.58M
Debt
$625.36M
Equity
$405.95M
Working capital
$331.36M
Debt to equity
1.54
Current ratio
2.74
Quick ratio
1.84
Net debt/EBITDA
6.7
Margins
Efficiency
Dividend
EBITDA margin
12.9%
Gross margin
59.8%
Net margin
-1.3%
Operating margin
2.7%
Return on assets
-0.9%
Return on equity
-2%
Return on invested capital
1.4%
Return on capital employed
0.9%
Return on sales
1.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIP stock price
How has the Ani Pharmaceuticals stock price performed over time
Intraday
-2.9%
1 week
-1.66%
1 month
-0.7%
1 year
0.54%
YTD
4.81%
QTD
4.81%
Financial performance
How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$555.46M
Gross profit
$332.11M
Operating income
$14.91M
Net income
-$7.09M
Gross margin
59.8%
Net margin
-1.3%
Ani Pharmaceuticals's net income has shrunk by 153% YoY and by 126% QoQ
The net margin has shrunk by 143% YoY and by 126% QoQ
ANIP's operating margin has dropped by 72% year-on-year and by 71% since the previous quarter
The company's operating income has shrunk by 70% QoQ and by 65% YoY
Growth
What is Ani Pharmaceuticals's growth rate over time
Valuation
What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
3
P/S
2.02
EV/EBIT
172.81
EV/EBITDA
23.7
EV/Sales
3.06
The company's EPS has shrunk by 147% QoQ
The P/B is 30% above the 5-year quarterly average of 2.3
The company's equity fell by 11% QoQ and by 6% YoY
Ani Pharmaceuticals's revenue has increased by 24% YoY and by 3.1% from the previous quarter
The price to sales (P/S) is 12% lower than the last 4 quarters average of 2.3 and 3.8% lower than the 5-year quarterly average of 2.1
Efficiency
How efficient is Ani Pharmaceuticals business performance
The ROA has plunged by 164% YoY and by 132% from the previous quarter
The return on equity has dropped by 163% year-on-year and by 135% since the previous quarter
Ani Pharmaceuticals's ROIC has plunged by 85% from the previous quarter and by 80% YoY
The company's return on sales has shrunk by 83% QoQ and by 81% YoY
Dividends
What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIP.
Financial health
How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 50% more than its total liabilities
ANIP's total liabilities has surged by 97% year-on-year and by 95% since the previous quarter
Ani Pharmaceuticals's total assets has increased by 45% YoY and by 40% from the previous quarter
The debt is 54% higher than the equity
The debt to equity has soared by 144% from the previous quarter and by 130% YoY
The debt has soared by 119% QoQ and by 119% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.